A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

Jorge P. Leguizamo,Mary G. Quinn,Chris H. Takimoto,Michael D. Liang,Abdel Salam Ismail,Janet Pang,William L. Dahut,Jean L. Grem

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

2003

Jorge P. Leguizamo
Mary G. Quinn
Chris H. Takimoto
Michael D. Liang
Abdel Salam Ismail
Janet Pang
William L. Dahut
Jean L. Grem

Purpose A phase I pharmacologic study was undertaken to determine the maximum tolerated dose (MTD), to characterize the pharmacokinetic profile, and to evaluate all toxicities of the aqueous colloidal dispersion formulation of 9-aminocampothecin (9-AC).

Keywords:

Pharmacodynamics
Pharmacology
Aminocamptothecin
Maximum tolerated dose
Pharmacokinetics
Medicine
Colloid
Dosage form
solid tumor
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations